Skip to main content
ASPI logo
ASPI
(NASDAQ)
ASP Isotopes Inc.
$4.04-- (--)
Loading... - Market loading

ASP Isotopes (ASPI) Company Profile

Complete business overview, executive team, trading details, and corporate information.

ASP Isotopes Inc.
ASPINasdaq Stock MarketMaterialsChemicals

About ASP Isotopes

ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-68, Nickel-64, and Xenon-129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. The company was incorporated in 2021 and is based in Dallas, Texas.

Company Information

SectorMaterials
IndustryChemicals
CEOPaul Elliot Mann
Founded2021
IPO DateNovember 10, 2022
Employees271
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Phone214 432 8219
Address
2200 Ross Avenue, Suite 4575E Dallas, Texas 75201 United States

Corporate Identifiers

CIK0001921865
CUSIP00218A105
ISINUS00218A1051
EIN87-2618235
SIC2890

Leadership Team & Key Executives

Dr. Gerdus Kemp M.D., Ph.D.
Medical Director and Chief Executive Officer of Pet Labs
Paul Elliot Mann C.F.A.
Executive Chairman and Chief Executive Officer
Heather Kiessling
Chief Financial Officer
Robert Ainscow
Chief Operating Officer
Nicholas Michael Mitchell
Co-Chief Operating Officer
Dr. Hendrik Strydom B. Sc, M. Sc, Ph.D.
Chief Technology Officer
Donald George Ainscow
EVice President, General Counsel and Secretary
Hendrik T. van Wyk
Head of Engineering
Dr. Xandra van Heerden Ph.D.
Head of Research and Development
Stefano Marani
President of Electronics and Space